AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Zinc phosphodiesterase ELAC protein 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9H777

UPID:

RNZ1_HUMAN

Alternative names:

Deleted in Ma29; ElaC homolog protein 1; Ribonuclease Z 1; tRNA 3 endonuclease 1; tRNase Z 1

Alternative UPACC:

Q9H777; Q9NS99

Background:

Zinc phosphodiesterase ELAC protein 1, also known as Deleted in Ma29, ElaC homolog protein 1, Ribonuclease Z 1, tRNA 3 endonuclease 1, and tRNase Z 1, plays a crucial role in cellular processes. It functions as a zinc phosphodiesterase with tRNA 3'-processing endonuclease activity, specifically involved in tRNA repair. This protein acts downstream of the ribosome-associated quality control (RQC) pathway, removing a 2',3'-cyclic phosphate from tRNAs after cleavage by ANKZF1, with subsequent processing by TRNT1.

Therapeutic significance:

Understanding the role of Zinc phosphodiesterase ELAC protein 1 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.